Antitumor activity of a new
cytostatic drug combination of
gemcitabine and
dioxadet have been studied in 86 female SHR mice transplanted with 5 x 10(6) of ascitic Ehrlich's
tumor cells each. All mice received a single injection of
gemcitabine,
dioxadet on combination 48 hams after
tumor cells introduction. In first series, experimental animals received maximal tolerable dose of
gemcitabine (25 mg/kg) and one half of
dioxadet maximal tolerable dose (2.5 mg/kg). In the second series of experiments, the animals received 5 mg/kg of
dioxadet along with the same
gemcitabine dose. Effect of drugs was compared using the time to
ascites detection,
body weight increase, and survival time.
Gemcitabine and
dioxadet administered separately and in combination inhibited the growth of ascitic Ehrlich's
tumor in the mice. In both series of experiments
antineoplastic activity of
gemcitabine and
dioxadet combination was significantly higher in comparison to the control groups receiving these drugs separately. The highest
antineoplastic activity of the
gemcitabine and
dioxadet combination was observed when the maximal tolerable doses of both drugs was applied. However, the
tumor cells growth was also significantly inhibited in mice receiving half of
dioxadet dose. Synergism of antitumor activity of
gemcitabine and
dioxadet was not accompanied by appreciable increase in toxicity.